Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000566 | 0.87 | LOXL2 (0.49) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL1999251 | 0.85 | MAPT (0.49) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL1999757 | 0.85 | RIPK1 (0.42) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL7544776 | 0.83 | MAPT (0.67) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL1996820 | 0.82 | AKR1B1 (0.48) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL27661443 | 0.79 | APP (0.52) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL1999968 | 0.78 | MAPT (0.52) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL30306714 | 0.77 | KMT2A (0.56) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL28984551 | 0.77 | KMT2A (0.56) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL4784061 | 0.76 | MMP13 (0.63) | MAPTKMT2AALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1722789-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | Amgen Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1296967-B1 | BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-7041691-B1 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC. | 2003-09-11 | — | — | US | disclosed |
| CN-1438998-A | Quinolinyl and benzothiazolyl PPAR-gamma modulators | TULARIK INC (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| CN-1368961-A | Compounds that modulate PPAR γ activity | TULARIK INC (US) | 2002-09-11 | — | — | CN | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | MAPT 708/4885KMT2A 3800/4885ALDH1A1 1672/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | MAPT 4694/4885KMT2A 4027/4885ALDH1A1 1831/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | MAPT 4679/4885KMT2A 3971/4885ALDH1A1 1739/4885 |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | MAPT 3145/4885KMT2A 2448/4885ALDH1A1 3157/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | MAPT 3145/4885KMT2A 2448/4885ALDH1A1 3157/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | MAPT 3019/4885KMT2A 2222/4885ALDH1A1 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.